Utility of the SomaLogic Cardiovascular Disease (CVD) Secondary Risk Panel for Cardiovascular Risk

Cardiovascular Diseases Clinical Trial

Official title:

A Pilot Study to Evaluate the Utility of the SomaLogic Cardiovascular Disease (CVD) Secondary Risk Panel as a a Tool to Stratify Cardiovascular Risk

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03599531
• Other study ID #: CLI1002F011
• Status: Completed
• Start date: June 13, 2017
• Est. completion date: October 10, 2020

Study information

• Verified date: March 2021
• Source: SomaLogic, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a prospective pilot study of participants who have stable coronary heart disease (CHD). Participants undergo risk stratification using the SomaLogic Cardiovascular Disease (CVD) Risk Panel blood test at baseline and again 4-12 months after the initial test. Participant surveys and chart abstractions are conducted at baseline and follow-up to collect feedback about the test report and actions taken. Care teams may consider using the risk information from the SomaLogic panel to address care gaps. Medical treatment decisions and recommendations are confirmed by established clinical methods, including blood pressure monitoring, body mass index (BMI), lipid and c-reactive protein (CRP) measurements, and physician's clinical judgment.

Description:

This is a prospective pilot study of participants who have stable coronary heart disease (CHD). Objectives of this study are to understand whether CVD Secondary Risk Panel scores change from baseline to follow-up (4-12 months after baseline) and actions taken, if any, based upon the results. Participants are surveyed to learn what the test results mean to them and assess if the results affect adherence to therapy and lifestyle choices (diet, exercise, alcohol, and tobacco use). In addition, this study will investigate the characteristics of patients that physicians choose to test with the CVD Secondary Risk Panel, and what actions the care team takes because of the results of the test. Medical treatment decisions and recommendations are confirmed by established clinical methods, including blood pressure monitoring, BMI, lipid and CRP measurements, and physician's clinical judgement. Chart abstractions and participants surveys occur at the baseline and follow-up visits, and charts may be abstracted annually for up to 10 years post enrollment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 244
• Est. completion date: October 10, 2020
• Est. primary completion date: October 10, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Age greater than or equal to 40

• Stable CHD documented by at least one of the following: history of myocardial infarction >6 months prior to study enrollment, angiographic evidence of at least 50% stenosis, abnormal CAC score, prior evidence of inducible ischemia by treadmill or nuclear testing, or a history of coronary revascularization

• Ability to provide informed consent

Exclusion Criteria:

• Inability or unwillingness to provide informed consent

• Less than 40 years of age

• History of myocardial infarction in the prior 6 months.

• Treatment for malignancy (other than basal or squamous cell carcinomas of the skin) within the last 2 years

• Pregnancy

• Individuals deemed ineligible by the Investigator

Related Conditions & MeSH terms

• Cardiovascular Diseases
• Cardiovascular Risk Factor

Locations

Country	Name	City	State
United States	Boulder Heart	Boulder	Colorado

Sponsors (1)

Lead Sponsor	Collaborator
SomaLogic, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Decrease in SomaLogic CVD Secondary Risk Score from baseline to follow-up.	Percent of participants whose CVD risk score decreased from baseline to follow-up. This is assessed on a numeric scale of 1 (lower risk) to 5 (higher risk).	12 months
Secondary	Motivation for adherence to medication assessed by a self-reported questionnaire.	Impact of the CVD Secondary Risk Score on patient adherence to therapy. Assessed by percent of patients whose motivation to adhere increased on a 5-point scale from baseline to follow-up.	12 months
Secondary	Motivation for a healthy diet assessed by a self-reported questionnaire.	Impact of the CVD Secondary Risk Score on diet. Assessed by percent of patients whose motivation for a healthy diet increased on a 5-point scale from baseline to follow-up.	12 months
Secondary	Motivation for exercise assessed by a self-reported questionnaire.	Impact of the CVD Secondary Risk Score on exercise. Assessed by percent of patients whose motivation to exercise increased on a 5-point scale from baseline to follow-up.	12 months
Secondary	Motivation for decreased alcohol use assessed by a self-reported questionnaire.	Impact of the CVD Secondary Risk Score on alcohol use. Assessed by percent of patients whose alcohol use decreased on a 5-point scale from baseline to follow-up.	12 months